Seven partners from Goodwin including Sarah Ashfaq, Olivia Uitto, Noelle Dubiansky, Erini Svokos, and Deepa Rich, share their views on what it takes to become a successful life sciences lawyer. Read the Chambers Associate article here.
Related Content
- InsightMarch 2, 2023
A Recap of Resilience: Goodwin’s Life Sciences Practice
- AlertApril 26, 2021
Congress Passes Legislation Codifying FDA’s “Active Moiety” Approach to Exclusivity Determinations
- AlertJanuary 6, 2021
Congress Enacts Amendments Affecting The Regulation Of Generic Drugs And Biosimilars
- VideoApril 23, 2020
Webinar Recording: Top of Mind Issues for Global Life Sciences Companies in the Era of COVID-19
- AlertApril 21, 2020
Qualifying for Immunity Under the U.S. PREP Act During COVID-19
- AlertApril 1, 2020
CMS Expands Availability of Advances on Medicare Reimbursement; U.S. CARES Act Increases Medicare Reimbursement Rates
- DRI, Rx for the DefenseAugust 8, 2019
Mobile Medical Apps: Understanding and Defending Against Products Liability Challenges
- PM360April 15, 2019
Words and Functionalities Matter: FDA Regulation of Consumer Software and Apps
- Press ReleaseNovember 8, 2024
AlloVir and Kalaris Therapeutics to Merge
- Press ReleaseOctober 2, 2024
Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones
- Awards and RankingsAugust 7, 2024
Benchmark Litigation Names Fourteen Goodwin Partners to 40 & Under Hot List 2024
- Press ReleaseJuly 8, 2024
Goodwin Represents the Underwriters For Taysha Gene Therapies $75 Million Public Offering
- Press ReleaseJune 28, 2024
Entrada Therapeutics Closes $100 Million Registered Direct Offering
- In the PressMay 24, 2024
A Changing Regulatory Landscape For Weight Loss Drugs (Law360)
- Press ReleaseMay 24, 2024
Aktis Oncology and Eli Lilly Collaborate on Discovery and Development of Novel Anticancer Radiopharmaceuticals; Aktis To Receive $60 Million Upfront and up to an Additional $1.1 Billion in Potential Milestones
- Press ReleaseMay 17, 2024
Proteologix to be Acquired by Johnson & Johnson For $850 Million